ANPEP and breast carcinoma: We show that these new APN analogues exhibit important antimitotic activity in breast cancer cells, as determined by a range of functional tests including cytotoxicity and clonogenic assays, as well as flow cytometry coupled to Annexin V-FITC/PI Double-Staining Fluorescence, in 2D and 3D cancer cells in culture.